Status:
UNKNOWN
Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab
Lead Sponsor:
Seoul St. Mary's Hospital
Conditions:
Complications of Diabetes Mellitus
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Purpose: To evaluate the acute changes in intraocular cytokines after intravitreal bevacizumab (IVB) in proliferative diabetic retinopathy. Design: Prospective, open-label, controlled, randomized int...
Eligibility Criteria
Inclusion
- Patients with proliferative diabetic retinopathy who were scheduled for PPV for vitreous hemorrhage or tractional retinal detachment (TRD)
Exclusion
- Eyes with any pharmacologic intervention on study eye within 6 months
- Eyes with panretinal photocoagulation on study eye within 3 months
- Eyes with any pharmacologic intervention on fellow eye within 3 months,
- History of ocular diseases other than diabetic retinopathy
- History of PPV on study eye
- History of systemic thromboembolic events including myocardial infarction and cerebrovascular accidents.
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2011
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01439178
Start Date
August 1 2011
End Date
November 1 2011
Last Update
September 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul Saint Mary's hospital
Seoul, Seoul, South Korea, 137-070